nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

01.07.2014 | main topic

Vitiligo: what’s new in the psycho-neuro-endocrine-immune connection and related treatments

verfasst von: Torello Lotti, MD, Matteo Zanardelli, Angelo Massimiliano D’Erme, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2014

Einloggen, um Zugang zu erhalten

Summary

Vitiligo is an acquired depigmentary skin disorder of unknown origin characterized by well-demarcated, white macules of varying size and distribution. Despite relevant new research and progresses, why melanocytes disappear to induce the characteristic achromic lesions of vitiligo is not fully understood. In spite of recent findings implicating genetic, immune and oxidative stress factors, the exact pathogenesis of vitiligo remains obscure. An innovative concept based on a functional cross-talk between the nervous and immune system is emerging. Neuropeptides released from peripheral nerve endings could synergize with new cytokines to adversely affect melanocyte function and viability. Evidence is increasing regarding the role of neuropeptides in the pathogenesis of vitiligo and a new winning approach to vitiligo therapy based on neuropeptides regulation is at the horizon.

Vorheriger Artikel Autoimmunity versus Autoinflammation - Friend or Foe?

Nächster Artikel Pathways of Tumor development and progression in Drug-induced Nonmelanoma Skin Cancer: a New Hope or the Next Great Confusion?

Laddha NC, Dwivedi M, Mansuri MS, Gani AR, Ansarullah M, Ramachandran AV, Dalai S, Begum R. Vitiligo: interplay between oxidative stress and immune system. Experimental Dermatology. 2013;22:245–50.PubMedCrossRef

Lotti T, Hercogova J, editors. Vitiligo: problems and solutions. New York: Marcel Dekker; 2004. S. 323–34.

Taieb A, Alomar A, Böhm M, Dell’anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M. The writing group of the Vitiligo European Task Force (VETF) in cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5–19.PubMedCrossRef

Lotti T, D’Erme AM. Vitiligo: a systemic disease. Clin Dermatol. 2014;32(3):430–34.PubMedCrossRef

Hercogová J, Schwartz RA, Lotti TM. Classification of vitiligo: a challenging endeavor. Dermatol Ther. 2012;25(Suppl 1):10–6.CrossRef

Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, Goh BK, Anbar T, Silva de Castro C, Lee AY, Parsad D, van Geel N, Le Poole IC, Oiso N, Benzekri L, Spritz R, Gauthier Y, Hann SK, Picardo M, Taieb A. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1–13.PubMedCentralPubMedCrossRef

Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90–100.PubMedCrossRef

Linthorst Homan MW, Sprangers MA, de Korte J, Bos JD, van der Veen JP. Characteristics of patients with universal vitiligo and health-related quality of life. Arch Dermatol. 2008;144(8):1062–4.PubMedCrossRef

Hann SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol. 1996;35(5 Pt 1):671–4.PubMedCrossRef

10.

Le Poole IC, Luiten RM. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun. 2008;10:227–43.PubMedCrossRef

11.

Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91.PubMedCrossRef

12.

Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity. 2001;34:65–77.PubMedCrossRef

13.

Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, De Benedette MA. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol. 2003 Sep;121(3):550–6.PubMedCrossRef

14.

Steitz J, Wenzel J, Gaffal E, Tuting T. Initiation and regulation of CD8 + T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur J Cell Biol. 2004;83(11–12):797–803.PubMedCrossRef

15.

Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol. 1991;97(6):1078–80.PubMedCrossRef

16.

Farrokhi S, Hojjat-Farsangi M, Noohpisheh MK, Tahmasbi R, Rezaei N. Assessment of the immune system in 55 Iranian patients with vitiligo. J Eur Acad Dermatol Venereol. 2005;19(6):706–11.PubMedCrossRef

17.

Lotti T, D’Erme AM, Hercogova J. The role of neuropeptides in the control of regional immunity. Clin Dermatol. (In press).

18.

Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev. 2006;86(4):1309–79.PubMedCrossRef

19.

Al’Abadie MSK, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol. 1994;131:160–5.

20.

Nellhiius G, Acquired unilateral vitiligo and poliosis of the head and subacute encephalitis with partial recovery. Neurology. 1970;20:965–74.CrossRef

21.

Silvan M. The psychological aspects of vitiligo. Cutis. 2004;73(3):163–7.PubMed

22.

Lotti T, Bianchi B, Ghersetich I, Brazzini B, Hercogova J. Can the brain inhibit inflammation generated in the skin? The lesson of gamma-melanocyte-stimulating hormone. Int J Dermatol. 2002;41(6):311–8.PubMedCrossRef

23.

Lotti T, Hautmann G, Panconesi E. Neuropeptides in skin. J Am Acad Dermatol. 1995;33(3):482–96.PubMedCrossRef

24.

Lotti T, Bianchi B, Panconesi E. Neuropeptides and skin disorders. The new frontiers of neuro-endocrine-cutaneous immunology. Int J Dermatol. 1999;38(9):673–5.PubMedCrossRef

25.

Urpe M, Pallanti S, Lotti T. Psychosomatic factors in dermatology. Dermatol Clin. 2005;23(4):601–8.PubMedCrossRef

26.

Urpe M, Buggiani G, Lotti T. Stress and psychoneuroimmunologic factors in dermatology. Dermatol Clin. 2005;23(4):609–17.PubMedCrossRef

27.

Vrijman C, Hosseinpour D, Bakker JG, Wolkerstorfer A, Bos JD, van der Veen JP, Luiten RM. Provoking factors, including chemicals, in Dutch patients with vitiligo. Br J Dermatol. 2013;168(5):1003–11.PubMedCrossRef

28.

Moretti S, Arunachalam M, Colucci R, Pallanti S, Kline JA, Berti S, Lotti F, Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. J Eur Acad Dermatol Venereol. 2012;26(7):861–7.PubMedCrossRef

29.

D’Erme AM, Zanieri F, Campolmi E, Santosuosso U, Betti S, Agnoletti AF, Cossidente A, Lotti T. Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study. J Eur Acad Dermatol Venereol. 2012 Sep 11.

30.

Farber EM. Psychoneuroimmunology and dermatology. Int J Dermatol. 1993;32:93–4.PubMedCrossRef

31.

Falabella R, Barona MI, Echeverri IC, Alzate A. Substance P may play a part during depigmentation in vitiligo. A pilot study. J Eur Acad Dermatol Venereol. 2003 May;17(3):355–6.PubMedCrossRef

32.

Slominski A, Wortsman J, Tuckey RC, Paus R. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol. 2007;265–266:143–9.PubMedCentralPubMedCrossRef

33.

Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25(11):563–8.PubMedCrossRef

34.

Slominski A, Wortsman J, Pisarchik A, Zbytec B, Linton EA, Mazurkiewicz JE, Wei ET. Cutaneous expression of corticotrophin releasing hormone (CRH), urocortin and CRH receptors. FASEB J. 2001;15(10):1678–93.PubMedCrossRef

35.

Slominski AT, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84:1155–228.PubMedCrossRef

36.

Kingo K, Aunin E, Karelson M, Philips MA, Rätsep R, Silm H, Vasar E, Soomets U, Kõks S. Gene expression analysis of melanocortin system in vitiligo. J Dermatol Sci. 2007;48(2):113–22.PubMedCrossRef

37.

Reimann E, Kingo K, Karelson M, Salum T, Aunin E, Reemann P, Abram K, Vasar E, Silm H, Kõks S. Analysis of the expression profile of CRH-POMC system genes in vitiligo skin biopsies. J Dermatol Sci. 2010;60(2):125–8.PubMedCrossRef

38.

Al-Hashimi M, Scott SW, Thompson JP, Lambert DG. Opioids and immune modulation: more questions than answers. Br J Anaesth. 2013;111(1):80–8.PubMedCrossRef

39.

Hristakieva E, Lazarova R, Lazarov N, et al. Markers for vitiligo related neuropeptides in human skin nerve fibres. Acta Med Croatica. 2000;54:53–7.PubMed

40.

Miniati A, Weng Z, Zhang B, Therianou A, Vasiadi M, Nicolaidou E, Stratigos AJ, Antoniu C, Theoharides TC. Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo. Clin Exp Dermatol. 2014;39(1):54–7.PubMedCrossRef

41.

Luger TA, Schwarz T. Evidence for an epidermal cytokine network. J Invest Dermatol. 1990;95:100–4.CrossRef

42.

Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol. 2008;17:139–40.PubMedCrossRef

Titel: Vitiligo: what’s new in the psycho-neuro-endocrine-immune connection and related treatments
verfasst von: Torello Lotti, MD
Matteo Zanardelli
Angelo Massimiliano D’Erme, MD
Publikationsdatum: 01.07.2014
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 13-14/2014
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-014-0288-7

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13-14/2014

Pyoderma gangrenosum: pathogenetic oriented treatment approaches

Bacterial antigens and molecular mimicry: the bridging common problematic link in the pathogenesis of sarcoidosis and sarcoid-like reactions: Isn’t it time to wake up?

Sarcoidosis vs. Sarcoid-like reactions: The Two Sides of the same Coin?

Autoimmunity versus Autoinflammation - Friend or Foe?

Cancer, Infection and Disturbances of The Integrity of Tissue Homeostasis: The Most Significant Triggers for Molecular Mimicry and Autoimmunity in Dermatology?

Pathways of Tumor development and progression in Drug-induced Nonmelanoma Skin Cancer: a New Hope or the Next Great Confusion?